Of the 234 patients who received at least one dose of commercial pembrolizumab in the first-line setting for NSCLC with a PD-L1 TPS of ≥50%, 195 (83.3%) had an ECOG PS of 0–1 and 39 (16.7%) had an ECOG PS of 2 at the start of immunotherapy treatment. This evidence concerns the gene CD274 and non-small cell lung carcinoma.